Cellectis: article published in the journal Molecular Therapy

(CercleFinance.com) - Cellectis gained nearly 3% on the Paris Bourse on Tuesday, following the publication in the scientific journal Molecular Therapy of an article on its CAR T cell design method for the treatment of recalcitrant solid tumors.


According to the biotech, this publication demonstrates the genome-editing capabilities of its proprietary 'Talen' technology for the design of allogeneic CAR T cells, which enable the targeting of solid tumors recalcitrant to immunotherapy while mitigating potential safety risks.

"Adoptive cell therapy based on CAR T cells is proving life-saving for many cancer patients", the company points out in a press release.

However, its therapeutic efficacy is limited to a few types of liquid tumors, with solid tumors proving particularly recalcitrant', it adds.

According to Cellectis, the use of its genome-editing technology presents an innovative CAR T cell engineering strategy designed to overcome these difficulties.

This approach, the company continues, enables efficient infiltration and targeting of triple-negative solid breast tumors in physiologically relevant mouse models, with no observable toxicity outside the tumor target.

Copyright (c) 2024 CercleFinance.com. All rights reserved.